Precision Medicine in Oncology® | Specialty

Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study

April 23rd 2014

A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma

Ellen T. Matloff on Changes to the Field of Genetic Testing

April 22nd 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.

Emerging Breakthroughs in Cancer Care: Toward a Revolution?

April 21st 2014

Medicine is undergoing a revolution that will transform the practice of healthcare, including oncology.

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents

April 4th 2014

The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain

The Retreatment Question: Research Suggests Benefits to Continuing Molecularly Targeted Therapy Beyond Progression

April 2nd 2014

The readministration of a cytotoxic antineoplastic agent is a well-established management paradigm in a number of malignancies, yet it is generally believed such a strategy may not prove beneficial if the patient experiences disease progression while receiving the therapy.

A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development

April 2nd 2014

Amid a growing recognition of the need to improve the process of developing oncology drugs, the novel I-SPY 2 clinical trial in breast cancer has demonstrated the potential to deliver new, effective treatment options more rapidly to patients who would most benefit while dramatically reducing the time and costs currently required to evaluate experimental therapies.

Breast Cancer Expert Offers Views on Promising Strategies

April 1st 2014

Now that targeted therapies are available for the treatment of various subtypes of breast cancer, and many novel agents are under investigation, it is important for the oncology community to follow the latest advancements to give patients the best available options.

Next-Generation EGFR Inhibitor Shows Promise in Resistant NSCLC

March 31st 2014

The next-generation EGFR inhibitor CO-1686 has demonstrated promising activity in T790M-positive patients with non-small cell lung cancer.

Precision Medicine-An Inevitable (Though Challenging) Goal!

March 26th 2014

There is no question that the era of precision medicine has arrived, and we need to embrace it and resolve together the challenges that come with it, including at the regulatory level.

Some Docs Hesitant to Embrace Genomic Tests That Identify Tumor Changes

March 25th 2014

A physician's confidence level in his genomic knowledge plays a significant role in attitudes towards genomic tests, especially in tests that look for changes in DNA that are taken from patients' tumor samples

Dr. Oh on a Biomarker Development Trial in mCRPC

March 20th 2014

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Tripathy on Personalized Therapies in Advanced BC

March 20th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.

Conclusion: Optimizing the Treatment of RCC

March 19th 2014

RCC Journal Highlights and Implications for Clinical Practice

March 19th 2014

Novel Therapies in Renal Cell Carcinoma

March 19th 2014

Evolving Role of Genomic Testing in RCC

March 19th 2014

Case Study: Utilizing Multiple Therapies in mRCC

March 19th 2014

Drug Holidays in Renal Cell Carcinoma

March 19th 2014

Case Study: Observation in Metastatic RCC

March 19th 2014